Ser800
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser800  -  Rb (mouse)

Site Information
PGGNIyIsPLksPYK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447980

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 23 , 25 ) , electrophoretic mobility shift ( 25 ) , flow cytometry ( 24 ) , immunoprecipitation ( 23 , 25 ) , mass spectrometry ( 1 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 16 ) , mutation of modification site ( 23 , 24 , 25 ) , phospho-antibody ( 2 , 3 , 15 , 17 , 18 , 19 , 20 , 21 , 22 ) , western blotting ( 2 , 3 , 15 , 17 , 18 , 19 , 22 , 23 , 24 )
Disease tissue studied:
anthrax infection ( 14 ) , bone cancer ( 24 ) , brain cancer ( 7 , 8 , 9 , 10 , 11 ) , breast cancer ( 24 ) , leukemia ( 17 ) , acute myelogenous leukemia ( 17 ) , neuroendocrine cancer ( 7 , 8 , 9 , 10 , 11 )
Relevant cell line - cell type - tissue:
32Dcl3 (myeloid) [FLT3 (mouse), transfection, chimera with human FLT3-ITD mutant (corresponding to wild type P36888 ( 16 ) , 32Dcl3 (myeloid) ( 16 ) , 3T3 (fibroblast) [CDC42 (human), transfection] ( 5 ) , 3T3 (fibroblast) [KRas (human), transfection] ( 5 ) , 3T3 (fibroblast) ( 5 ) , B lymphocyte [CCND1 (mouse), homozygous knockout] ( 22 ) , B lymphocyte-spleen ( 15 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 1 ) , brain ( 7 , 8 , 9 , 10 , 11 ) , C2C12 (myoblast) ( 19 ) , C33-A (cervical) ( 23 ) , COS (fibroblast) ( 23 , 25 ) , granulosa ( 2 ) , macrophage-peritoneum [MPRIP (mouse), homozygous knockout] ( 6 ) , MCF-10A (breast cell) ( 24 ) , MEF (fibroblast) ( 18 ) , MEF (fibroblast) [IGF1R (mouse)] ( 21 ) , MEF (fibroblast) [p53 (mouse), homozygous knockout] ( 12 ) , oocyte ( 2 ) , Saos-2 (bone cell) ( 24 ) , spleen ( 14 ) , T lymphocyte-spleen ( 13 ) , uterus ( 20 )

Upstream Regulation
Regulatory protein:
Akt1 (mouse) ( 18 ) , CDC42 (mouse) ( 5 ) , CDK2 (mouse) ( 3 ) , CDK4 (human) ( 3 ) , FLT3 (mouse) ( 16 ) , HBpX (retrovirus) ( 17 ) , KRas (mouse) ( 5 ) , p73 (mouse) ( 19 ) , PAK4 (mouse) ( 5 ) , TSC2 (mouse) ( 18 )
Putative in vivo kinases:
CDK4 (mouse) ( 21 ) , CDK6 (mouse) ( 21 )
Treatments:
anti-CD40 ( 15 ) , anti-IgM ( 15 ) , DMSO ( 19 ) , estradiol ( 20 ) , high_glucose ( 3 ) , IL-3 ( 22 ) , IL-6 ( 22 ) , lithium ( 20 ) , progesterone ( 20 ) , SB202190 ( 17 ) , SB600125 ( 17 ) , SCF ( 22 ) , serum ( 18 , 21 )

Downstream Regulation
Effects of modification on Rb:
molecular association, regulation ( 23 ) , protein conformation ( 25 )
Effects of modification on biological processes:
cell cycle regulation ( 24 ) , transcription, inhibited ( 24 )
Inhibit interaction with:
E2F1 (human) ( 23 )

References 

1

Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia
28852199   Curated Info

2

Yang QE, et al. (2015) Inactivation of Retinoblastoma Protein (Rb1) in the Oocyte: Evidence That Dysregulated Follicle Growth Drives Ovarian Teratoma Formation in Mice. PLoS Genet 11, e1005355
26176933   Curated Info

3

Gillam MP, et al. (2015) MEN1 tumorigenesis in the pituitary and pancreatic islet requires Cdk4 but not Cdk2. Oncogene 34, 932-8
24531709   Curated Info

4

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

5

Gnad F, et al. (2013) Systems-wide Analysis of K-Ras, Cdc42, and PAK4 Signaling by Quantitative Phosphoproteomics. Mol Cell Proteomics 12, 2070-80
23608596   Curated Info

6

Wu X, et al. (2012) Investigation of receptor interacting protein (RIP3)-dependent protein phosphorylation by quantitative phosphoproteomics. Mol Cell Proteomics 11, 1640-51
22942356   Curated Info

7

Guo A (2011) CST Curation Set: 12732; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

8

Guo A (2011) CST Curation Set: 12733; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

9

Guo A (2011) CST Curation Set: 12734; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

10

Guo A (2011) CST Curation Set: 12735; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

11

Guo A (2011) CST Curation Set: 12739; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

12

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

13

Navarro MN, et al. (2011) Phosphoproteomic analysis reveals an intrinsic pathway for the regulation of histone deacetylase 7 that controls the function of cytotoxic T lymphocytes. Nat Immunol 12, 352-61
21399638   Curated Info

14

Manes NP, et al. (2011) Discovery of mouse spleen signaling responses to anthrax using label-free quantitative phosphoproteomics via mass spectrometry. Mol Cell Proteomics 10, M110.000927
21189417   Curated Info

15

Damdinsuren B, et al. (2010) Single round of antigen receptor signaling programs naive B cells to receive T cell help. Immunity 32, 355-66
20226693   Curated Info

16

Choudhary C, et al. (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 36, 326-39
19854140   Curated Info

17

Wang WH, Hullinger RL, Andrisani OM (2008) Hepatitis B virus X protein via the p38MAPK pathway induces E2F1 release and ATR kinase activation mediating p53 apoptosis. J Biol Chem 283, 25455-67
18606816   Curated Info

18

Skeen JE, et al. (2006) Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 10, 269-80
17045205   Curated Info

19

Cam H, et al. (2006) p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell 10, 281-93
17045206   Curated Info

20

Chen B, et al. (2005) Progesterone inhibits the estrogen-induced phosphoinositide 3-kinase-->AKT-->GSK-3beta-->cyclin D1-->pRB pathway to block uterine epithelial cell proliferation. Mol Endocrinol 19, 1978-90
15845746   Curated Info

21

Kozar K, et al. (2004) Mouse development and cell proliferation in the absence of D-cyclins. Cell 118, 477-91
15315760   Curated Info

22

Mohamedali A, et al. (2003) Cyclin D2 controls B cell progenitor numbers. J Leukoc Biol 74, 1139-43
14612431   Curated Info

23

Brown VD, Phillips RA, Gallie BL (1999) Cumulative effect of phosphorylation of pRB on regulation of E2F activity. Mol Cell Biol 19, 3246-56
10207050   Curated Info

24

Buchmann AM, Swaminathan S, Thimmapaya B (1998) Regulation of cellular genes in a chromosomal context by the retinoblastoma tumor suppressor protein. Mol Cell Biol 18, 4565-76
9671466   Curated Info

25

Hamel PA, Gill RM, Phillips RA, Gallie BL (1992) Regions controlling hyperphosphorylation and conformation of the retinoblastoma gene product are independent of domains required for transcriptional repression. Oncogene 7, 693-701
1565466   Curated Info